Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
Titel:
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
Auteur:
Brown, J. P. Roux, C. Ho, P. R. Bolognese, M. A. Hall, J. Bone, H. G. Bonnick, S. Bergh, J. P. van den Ferreira, I. Dakin, P. Wagman, R. B. Recknor, C.